SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently facing intense selling pressure and volatility as traders weigh macro risks involving international tensions and potential central bank policy shifts against ongoing institutional support. The community remains deeply divided, with many debating whether the current price action is a structural bear trap or a sign of an impending larger correction.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is seeing significant trading activity driven by reports of President Trump's substantial position in the company and ongoing institutional rotation from semiconductor stocks into software. While some investors fear AI disruption in the SaaS sector, many community members are expressing strong conviction in ServiceNow's durable subscription model and its role as a critical enterprise workflow engine.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending as investors debate management's decision to scale back weekly Ethereum accumulation while monitoring the potential passage of the crypto-focused CLARITY Act. The community remains sharply divided, with some betting on long-term value from institutional tokenization efforts while others express frustration over share price volatility and dilution concerns.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently under the spotlight as the market closely monitors the upcoming Senate Banking Committee markup of the Clarity Act, which is driving significant speculation and volatility. Community members are actively debating the potential regulatory implications, with many traders analyzing price action to determine if the asset is entering a period of accumulation or facing further downside pressure.

Entrepreneurshares Series Trust - ERShares Private-Public Crossover ETF

Investors are flocking to XOVR as a liquid proxy for SpaceX exposure ahead of anticipated IPO developments, favoring its trading proximity to net asset value compared to more volatile peers. The community remains divided between those viewing it as a safer, long-term foundational play for private market access and those skeptical of the fund's private equity valuation and disclosure transparency.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The iShares 20+ Year Treasury Bond ETF (TLT) is experiencing significant downward pressure as market participants grapple with a combination of persistent energy-driven inflation and concerns over the Federal Reserve's future interest rate trajectory. Investors are actively debating whether these falling bond prices represent a structural shift that will lead to higher long-term yields or a potential buying opportunity contingent on a resolution to regional geopolitical tensions and subsequent central bank policy pivots.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing stock is experiencing significant volatility driven by market disappointment over a smaller-than-anticipated aircraft order from China, despite the company's massive long-term backlog and expectations of a strategic turnaround. Investors are actively debating whether the current price action reflects a legitimate 'sell the news' reaction to a perceived diplomatic underperformance or an opportunity to buy into a recovering industrial giant ahead of upcoming management insights.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Market participants are actively debating the potential for a deeper pullback as rising bond yields, sustained oil price volatility, and geopolitical tensions in the Middle East test investor confidence. Community sentiment remains divided between those expecting a 'buy the dip' opportunity and those bracing for further downside, with many closely monitoring upcoming earnings and macroeconomic indicators for signs of a trend reversal.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust (SLV) is facing intense market volatility as investors grapple with conflicting signals from cooling demand, inflationary pressures, and ongoing geopolitical tensions. The community is sharply divided between bulls betting on industrial demandspecifically from the AI and data center sectorsand bears who argue that the recent price surge has peaked and is vulnerable to a broader correction.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is currently trending as investors weigh its aggressive pivot toward AI agent infrastructure against concerns over regulatory hurdles, particularly following recent operational pauses for its autonomous robotaxi fleet. While the community remains deeply polarized between bullish sentiment regarding the company's long-term cloud and AI growth potential and bearish warnings about systemic risks in Chinese tech stocks, active discussion is dominated by Baidu's upcoming conference updates and the potential for a significant earnings re-rating.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to...

Here's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now

Applied Therapeutics (APLT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--ALEX, DVS, DXLG, and APLT

SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--ALEX, DVS, DXLG, and APLT SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--ALEX, DVS, DXLG, and APLT...

APLT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Applied Therapeutics, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Therapeutics, Inc. (NASDAQ: APLT) to Cycle Group Holdings Limited for $0.088 per share in cash plus one...

Applied Therapeutics (APLT) Upgraded to Buy: Here's Why

Applied Therapeutics (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

<ul class="summary-bullets"><li>The company stated that there is no deadline for the strategic alternative finding process.</li><li>The firm also noted that it intends to request an additional meeting with the FDA to decide on a design for its late-stage study of Govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency.</li></ul> Applied Therapeutics, Inc. (APLT) said on Thursday that it is laying off approximately 46% of its workforce as it seeks to conserve cash, while its Board of Directors explores strategic alternatives for the company.The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions to maximise shareholder value, the company<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/20/3191771/0/en/Applied-Therapeutics-Announces-Corporate-Updates.html"> said</a>. There is no deadline for the process, Applied Therapeutics noted, while also adding that the review might not result in a transaction.<h2 class="st-heading-2">Drug Pipeline Updates</h2>The company also said it intends to request an additional meeting with the U.S. Food and Drug Administration to decide on a design for its late-stage study of Govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase (SORD) Deficiency. In this disorder, the body can’t properly metabolize sorbitol, leading to its toxic accumulation that damages peripheral nerves and causes progressive symptoms like limb weakness, numbness, and difficulty walking.The company held a meeting with the FDA in the third quarter and is now evaluating the meeting minutes and follow-up correspondence.It is also evaluating the next steps for developing Govorestat for the treatment of Classic Galactosemia, a disorder in which the body cannot break down the sugar galactose. &nbsp;Govorestat is the company’s lead drug candidate for the treatment of CNS rare metabolic diseases or inherited conditions affecting the brain, such as Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency, and phosphomannomutase 2 congenital disorder of glycosylation.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/APLT">APLT shares</a> traded marginally in the red at the time of writing. On Stocktwits, retail sentiment stayed within the ‘extremely bullish’ territory over the past 12 months while message volume stayed at ‘extremely high’ levels.APLT shares fell 67% this year and by 97% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-procures-1.5-billion-loan-to-grow-its-pipeline-beyond-vaccines/cLPA0dfREaR">Moderna Secures $1.5B Credit Facility As It Seeks To Pivot Away From Vaccines</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Applied Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options

The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.

Equity

The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.


Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain

Applied Therapeutics stock falls after FDA feedback prompts another Type C meeting to discuss the Phase 3 plan for its CMT-SORD drug govorestat.read more...

Halper Sadeh LLC Encourages Applied Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Applied Therapeutics, Inc. (NASDAQ: APLT) breached their fiduciary duties to shareholders. If...

Retail buzz&nbsp;surrounding Applied Therapeutics Inc spiked&nbsp;late Sunday after the company revealed full 12-month clinical results alongside new 18- and 24-month topline data from&nbsp;a midstage trial of govorestat to treat Charcot-Marie-Tooth disease caused by Sorbitol Dehydrogenase deficiency (CMT-SORD).MRI observations showed that govorestat treatment slowed disease progression at 24 months, while keeping blood sorbitol levels low and improving functional outcomes and patient-reported metrics.The 12-month data revealed a statistically significant increase in the CMT-Health Index (CMT-HI) and a connection between sorbitol reductions and enhanced mobility and balance.&nbsp;CMT-SORD is a rare, progressive neuromuscular disorder that leads to nerve damage, muscle weakness, and mobility impairment.The company acknowledged that the primary endpoint of the 10MWRT at 12 months failed to show statistical significance, which led to its removal from the CMT-FOM clinical outcomes tool.Patients demonstrated good tolerance for govorestat, maintaining safety for two years.&nbsp;90% of eligible patients continued participating in the open-label extension study.&nbsp;Applied Therapeutics said it will submit a New Drug Application (NDA) for govorestat by 2025.The company’s shares surged 22.8% to close at $0.60 on Friday, with a further 1.2% gain in after-hours trading.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘a 629% surge in 24-hour message volume.Some retail traders expressed optimism about Applied Therapeutics' prospects, with one suggesting that the stock’s sharp decline in December may have been overdone and that the current low valuation presents a “monster opportunity.”<stembedurl>https://stocktwits.com/BuyThemCheapStackemDeep/message/615044473</stembedurl>Another pointed to the positive impact of govorestat on disease progression in CMT-SORD, noting that in a rare condition with no approved treatments, the available data could support regulatory approval.<stembedurl>https://stocktwits.com/Aawilliam2003/message/615043651</stembedurl>The stock has declined 33% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug

The company said that Govorestat slowed disease progression and improved patient outcomes in CMT-SORD, a rare hereditary neuropathy. The company plans to submit an NDA in 2025 amid strong retail investor interest.

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

APLT
Applied Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest APLT News

APLTApplied Therapeutics Inc